8SJ.F SHANGHAI JUNSHI BIO YC1
- Market cap
- EUR 1.82B
- P/E
- -
- P/B
- 2.31x
- ROE
- -13.9%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is 8SJ.F undervalued?
Graham numberThe Graham number of SHANGHAI JUNSHI BIO YC1 cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
SHANGHAI JUNSHI BIO YC1 fundamental analysis
No fundamental analysis for SHANGHAI JUNSHI BIO YC1 yet.
SHANGHAI JUNSHI BIO YC1 stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About SHANGHAI JUNSHI BIO YC1
Shanghai Junshi Biosciences Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of various drugs in China. The company's product pipelines include Tifcemalimab, an anti- B and T lymphocyte attenuator mAB which is in phase III clinical trial to treat lung cancer and lymphocyte; Roconkibart, an anti-interleukin-17A monoclonal antibody which is in phase III clinical trial to treat psoriatic and spondylitis; JS001sc, a subcutaneou…
Full company profileSHANGHAI JUNSHI BIO YC1 financial statements
SHANGHAI JUNSHI BIO YC1 annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 4.02B | 1.45B | 1.50B | 1.95B | 2.50B |
| Gross Profit | 2.77B | 927M | 835M | 1.45B | 1.98B |
| Operating Income | -593M | -2.72B | -2.45B | -1.30B | -925M |
| EBITDA | - | -2.35B | -2.16B | -1.02B | -631M |
| Net Income | -719M | -2.39B | -2.28B | -1.28B | -841M |
| EPS | -0.79 | -2.43 | -2.31 | -1.30 | -0.82 |
| Balance Sheet | |||||
| Total Assets | 11.1B | 12.6B | 11.4B | 10.8B | 12.4B |
| Total Liabilities | 2.72B | 2.78B | 4.02B | 4.85B | 6.33B |
| Shareholders' Equity | 7.96B | 9.50B | 7.17B | 5.88B | 6.05B |
| Cash & Short-term Investments | 3.50B | 6.00B | 3.78B | 2.49B | 2.59B |
| Cash Flow | |||||
| Operating Cash Flow | -642M | -1.78B | -2.01B | -1.44B | -515M |
| Capital Expenditure | 886M | 394M | 833M | 691M | 768M |
| Free Cash Flow | -1.53B | -2.17B | -2.85B | -2.13B | -1.28B |
| Ratios | |||||
| ROE | -9.0% | -25.1% | -31.8% | -21.8% | -13.9% |
| ROA | -6.5% | -19.0% | -20.1% | -11.9% | -6.8% |
| Net Profit Margin | -17.9% | -164.2% | -151.9% | -65.8% | -33.7% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
SHANGHAI JUNSHI BIO YC1 dividends
SHANGHAI JUNSHI BIO YC1 has not paid dividends in the last 5 fiscal years.
Who owns SHANGHAI JUNSHI BIO YC1
- Insiders 19.62%
- Institutions 23.42%
- Public & others 56.96%
- Shares outstanding 260M
- Free float 753M
SHANGHAI JUNSHI BIO YC1 company profile
- Company name
- SHANGHAI JUNSHI BIO YC1
- Ticker
- 8SJ.F
- ISIN
- CNE100003FF7
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 2,903
- Fiscal year end
- December
- Address
- Building 7, Shanghai, China, 200126
- Phone
- 86 21 6105 8800
- Website
- junshipharma.com
About SHANGHAI JUNSHI BIO YC1
Shanghai Junshi Biosciences Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of various drugs in China. The company's product pipelines include Tifcemalimab, an anti- B and T lymphocyte attenuator mAB which is in phase III clinical trial to treat lung cancer and lymphocyte; Roconkibart, an anti-interleukin-17A monoclonal antibody which is in phase III clinical trial to treat psoriatic and spondylitis; JS001sc, a subcutaneous injection which is in phase III clinical trial for the treatment of tumors; JS105, an oral small molecule inhibitor targeting PI3K-a which is in phase III clinical trial to treat gynecological tumors; and JS107, an antibody-drug conjugate which is in phase III clinical trial for the treatment of gastrointestinal cancer. It also develops JS212, JS213, JS207, JS203, JS125, JS214, and JS214 which is in phase I/II clinical trial for the treatment of tumors; JS111, a small molecule inhibitor targeting which is in phase I/II clinical trial to treat NSCLC; JS110, a small molecule inhibitor of the nuclear export protein XPO1 which is in phase I/II clinical trial to treat endometrial cancer; JS007, a recombinant humanized anti-Cytotoxic T lymphocyte associated antigen-4 monoclonal antibody which is in phase I/II clinical trial to treat lung cancer and melanoma; and JT002, A small nucleic acid immunomodulator which is in phase I/II clinical trial for the treatment of seasonal allergic rhinitis. In addition, the company offers TUOYI/LOQTORZI/ZYTORVI for tumors; JUNMAIKANG for the treatment of rheumatoid arthritis, ankylosing spondylitis, psoriasis, Crohn's disease, uveitis, polyarticular juvenile idiopathic arthritis, pediatric plaque psoriasis, and pediatric Crohn's disease; VV116/JT001, an oral nucleoside analog drug; and JUNSHIDA to treat hyperlipidemia. The company was founded in 2012 and is headquartered in Shanghai, People's Republic of China.
SHANGHAI JUNSHI BIO YC1 management
10- Mr. Jun XiongExecutive Chairman · born 1974
- Mr. Cong LiCo-CEO & Executive Director · born 1964
- Dr. Jianjun Zou M.D., Ph.D.GM, CEO & Executive Director · born 1971
- Dr. Ning Li M.D., Ph.D.Executive Vice-Chairman of the Board · born 1961
- Mr. Baohong XuChief Financial Officer · born 1979
- Mr. Zhuobing ZhangDeputy GM & Executive Director · born 1967
- Dr. Gang WangChief Quality Officer, Senior VP of Industry Affairs & Executive Director · born 1957
- Dr. Xin LiSenior VP of Government Affairs & Executive Director · born 1979
- Mr. Zhengyu WangJoint Company Secretary · born 1995
- Ms. Lu YuanAssistant to GM & Chief of Internal Audit Department · born 1982